Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: insulin detemir Clear all

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, insulin NPH; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 placebo, BI 10773 low dose, BI 10773 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin detemir, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 28
States / cities: Anaheim, California • Huntington Beach, California • Inglewood, California + 24 more

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: insulin aspart, insulin detemir; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: Faster-acting insulin aspart, insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 116
States / cities: Mobile, Alabama • Tucson, Arizona • Anaheim, California + 87 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2963016, LANTUS®, Oral Antihyperglycemic Medication; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 66
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more

Conditions: Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions: Exenatide; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cystic Fibrosis
Interventions: novolog insulin, levemir insulin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 10 Years to 25 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 20
States / cities: Fresno, California • Mission Viejo, California • Miami, Florida + 15 more

Conditions: Diabetes Mellitus, Type II
Interventions: Liraglutide, Insulin; Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Type 1 Diabetes
Interventions: Pramlintide, Exenatide, Insulin; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 12 Years to 21 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 550,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, basal insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 32
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 27 more

Conditions: Diabetes, Gestational, Diabetes, Type 2
Interventions: Insulin; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus Type 2
Interventions: Insulin Lispro Protamine Suspension, Detemir; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Hueytown, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more

Conditions: Diabetes
Interventions: Detemir; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 19 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin Detemir, Insulin NPH; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 5,652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 407
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: FlexTouch®, FlexPen®; Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 65
States / cities: Burlingame, California • Concord, California • Encino, California + 59 more

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Insulin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Philadelphia, Pennsylvania

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia

Search by objective public record fields.

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Oral Anti Diabetic Agents in the Hospital

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

DETERMINE: Detemir vs NPH

Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery